On 10 March 2005, orphan designation (EU/3/05/269) was granted by the European Commission to Janssen-Cilag International N.V., Belgium, for tipifarnib for the treatment of acute myeloid leukaemia.
The sponsorship was transferred to TMC Pharma Services Ltd, United Kingdom, in June 2015 and subsequently to TMC Pharma (EU) Limited, Ireland, in December 2019.
|Disease / condition||
Treatment of acute myeloid leukaemia
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;